A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page.(May 2024) (Learn how and when to remove this message)
Roivant Sciences Ltd.
Company type
Public
Traded as
Nasdaq: ROIV
S&P 400 component
Industry
Pharmaceuticals
Founded
April 7, 2014; 10 years ago (2014-04-07)
Founder
Vivek Ramaswamy
Headquarters
London, United Kingdom
Key people
Matt Gline (CEO)
Revenue
US$61 million (fiscal 2023)
Net income
US$−1.1 billion (fiscal 2023)
Total assets
US$2.39 billion (fiscal 2023)
Total equity
US$1.61 billion (fiscal 2023)
Owner
Vivek Ramaswamy (10.5%)
Number of employees
≈ 904 (March 2023)
Website
roivant.com
Footnotes / references [1][2]
Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.
^"FY2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commisssion. 28 June 2023. Archived from the original on 26 August 2023. Retrieved 26 August 2023.
^"2023 Proxy Statement". Archived from the original on 2023-09-02. Retrieved 2023-09-02.
RoivantSciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology...
August 9, 1985) is an American entrepreneur and politician. He founded RoivantSciences, a pharmaceutical company, in 2014. In February 2023, Ramaswamy declared...
understand and combat the COVID-19 pandemic." Datavant was co-founded by RoivantSciences in 2017 with a focus on data management in support of clinical trials...
candidate Vivek Ramaswamy in October 2014 as a wholly owned subsidiary of RoivantSciences, which was itself founded in May 2014. In December 2014, Axovant acquired...
RoivantSciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients". roivant...
OurCrowd Oyo Rooms Ping An Good Doctor PolicyBazaar Rappi Revolut RoivantSciences Slack Swiggy The Hut Group Tractable (company) Uber Unacademy View...
London IPO". CNN. Retrieved 6 April 2021. "Biotech holding company RoivantSciences raised $200M in funding at a whopping $7B valuation". TechCrunch. Oath...
executive chairman of Strive Asset Management (2022–2023) and CEO of RoivantSciences (2014–2021) (ran as a Republican; endorsed Trump) Dave Smith, stand-up...
Prakash Puram, president and CEO of iXmatch Vivek Ramaswamy, founder of RoivantSciences, candidate in the 2024 Republican Party presidential primaries Vivek...
personal investment” in Datavant which was initially supported by RoivantSciences, a healthcare company owned by Ramaswamy. In 2018, May helped lead...
executive chairman of Strive Asset Management (2022–2023) and CEO of RoivantSciences (2014–2021) (ran as a Republican; endorsed Trump) Dave Smith, stand-up...
Ohio Executive chairman of Strive Asset Management (2022–2023) CEO of RoivantSciences (2014–2021) Ohio February 21, 2023 January 15, 2024 (endorsed Trump)...
Ohio Executive chairman of Strive Asset Management (2022–2023) CEO of RoivantSciences (2014–2021) Ohio February 21, 2023 January 15, 2024 (endorsed Trump)...
Candidate for U.S. President (2024) $1 billion Founder and CEO of RoivantSciences and strive asset management [1] Michael Bloomberg Democratic (before...
Wirecard, RoivantSciences, Brazilian logistics company Loggi, Energy Vault, Creditas and Cambridge Mobile Telematics (CMT). RoivantSciences' founder...
Rockwell Automation ROK Industrials Electrical Components & Equipment RoivantSciences ROIV Health Care Roku ROKU Communication Services Rollins ROL Industrials...
and The Journal of Portfolio Management. He is also a director of RoivantSciences. His awards include Batterymarch, Guggenheim, and Sloan fellowships;...
myelodysplastic syndrome. In 2019, Medigene partnered with Roivant and Sinovant to launch Cytovant Sciences, which focuses on developing cellular therapies in...
Burger, Ludwig; Revill, John (23 October 2023). "Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal". Reuters. "Roche Holding Bilanz...
Global Information
US$61 million (fiscal 2023)
US$−1.1 billion (fiscal 2023)